Swedish Orphan Biovitrum AB (publ)
XMUN:B6E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Economic Moat
Swedish Orphan Biovitrum has a narrow economic moat
Patents and temporary market protections on some of Sobi’s rare-disease medicines delay direct copies, helping it retain sales while rivals develop and test alternatives. Other medicines can still treat the same conditions, so these protections provide a limited barrier rather than keeping all competitors out.
What protects Swedish Orphan Biovitrum from competitors
Intangible Assets
Patents and market-exclusivity rights on selected Sobi medicines make it harder for rivals to sell direct copies in the rare-disease markets those treatments serve. This can protect sales while the rights remain in force, although competing treatments may still be available.
What could weaken Swedish Orphan Biovitrum's moat
1 risk to watch
What could happen to the source of the moat and how it would weaken it